Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Size to Reach $38.26 Billion by 2029 | Growth at 8.6% CAGR Forecast

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

What is the Projected Market Size of the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Industry?
The market for programmed death (PD)-1 non-small cell lung cancer has seen significant growth over the years. The market, currently valued at $25.23 billion in 2024, is expected to increase to $27.50 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%. The substantial growth during this period can be credited to a growing number of non-small cell lung cancer cases, increased use of immunotherapy in developed countries, heightened awareness around cancer screening, more approvals for monoclonal antibodies, and increased healthcare spending.

What Will Be the Size of the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market by 2029?
Significant growth is expected in the programmed death (PD)-1 non-small cell lung cancer market size over the next few years. The market is projected to reach $38.26 billion in 2029 with a compound annual growth rate (CAGR) of 8.6%. This projected growth during the forecast period is attributed to factors such as escalated investments in infrastructure specific to cancer, enhanced patient access to biologics in upcoming markets, an escalating global aging population, increased reimbursement support for immunotherapies, and improved success rates of PD-1 inhibitors clinically. Key trends during this period encompass advancements in technology for biomarker testing, progress in combination immunotherapy protocols, investments in personalized treatment plans, relentless research and development for new PD-1 inhibitors and innovations in immunotherapy checkpoint blockade mechanisms.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/programmed-death-pd-1-non-small-cell-lung-cancer-global-market-report

What Are the Key Drivers Accelerating Growth in the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
The use of personalized treatments is anticipated to drive the expansion of the programmed death (PD)-1 non-small cell lung cancer market. These treatments are devised to cater to an individual's genetic makeup, lifestyle, and unique disease traits, resulting in more targeted and successful outcomes. The surge in personalized treatments comes from the increasing availability of genomic profiling and biomarker testing. These technologies can identify specific mutations and biological markers, enabling healthcare professionals to choose therapies most likely to succeed for each person. Personalized treatments guide programmed death (PD)-1 non-small cell lung cancer (NSCLC) therapies based on a patient's genetic makeup, cancer characteristics, and immune response. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, reported that the US Food and Drug Administration (FDA) greenlit 16 new personalized treatments for rare diseases in 2023, a big leap from the 6 approved in 2022. Hence, the growing preference for personalized treatments is fueling the advancement of the programmed death (PD)-1 non-small cell lung cancer market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25888&type=smp

How Is the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmented by Type, Application, and Region?
The programmed death (pd)-1 non-small cell lung cancer market covered in this report is segmented -

1) By Drug Type: Monotherapy, Combination Therapy
2) By Line of Therapy: First-line Treatment, Second-line And Beyond
3) By End User: Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users

Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine, Other Combination Drug Types

What Are the Key Trends Driving Growth in the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Leading firms within the programmed death (PD)-1 non-small cell lung cancer domain are prioritizing the execution of clinical tests for unique treatments, such as monotherapy, in an effort to enhance patient results. Monotherapy is a treatment method that utilizes a singular drug or therapy to manage an illness or condition. For example, Akeso, Inc., a biopharmaceutical organization based in China, reported affirmative results in March 2025 from its Phase III HARMONi-2 trial where Ivonescimab (AK112) was used in conjunction with chemotherapy as a premier treatment for advanced non-small cell lung cancer (NSCLC). The trial achieved its main objective by notably lengthening the period of progression-free survival in comparison to pembrolizumab, underscoring the therapeutic potential of the dual-targeted bispecific antibody.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25888&type=smp

Who Are the Leading Companies Driving Growth in the Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

Which Is the Leading Region in the Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market?
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.